Silexion doses first patient in Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer

Silexion Therapeutics Corp

First patient dosed at Tel Aviv Sourasky Medical Center (Ichilov) in Israel on September 30, 2026, Silexion announced.
Phase 2/3 trial evaluates SIL204 plus standard chemotherapy versus chemotherapy alone in unresectable Stage 3 LAPC with confirmed KRAS mutation.
Trial starts with a safety run-in of about 18 patients, then expands to a randomized cohort of about 166 patients.
SIL204 uses EUS-guided intratumoral delivery plus subcutaneous abdominal injections; additional Israel and Germany sites are expected to join.
CEO Ilan Hadar called the dosing a defining operational and clinical milestone for Silexion's lead RNAi program.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.